PT141 10mg Canada

Technical Specifications

Compound Name: PT141 (Bremelanotide research peptide)
Quantity: 10mg per vial
Format: Lyophilized peptide powder
Peptide Length: 7 amino acids (cyclic heptapeptide analogue)
Molecular Weight: Approximately 1025.2 g/mol
Purity Standard: ≥98% (HPLC, batch dependent)
Research Classification: Investigational peptide – laboratory research use only

PT141 10mg Canada is supplied as a lyophilized synthetic peptide intended exclusively for laboratory and analytical applications. Each vial contains 10 milligrams of the cyclic melanocortin analogue prepared under controlled handling and quality verification standards appropriate for research material distribution.

This product is classified as an investigational research compound and is not authorized for therapeutic, diagnostic, or consumer use in Canada when supplied in research format.

Research Overview

PT141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) developed for research into melanocortin receptor signalling. It is structurally related to Melanotan peptides and has been studied for its receptor interaction profile in experimental systems.

Research involving PT141 10mg Canada typically focuses on melanocortin receptor subtypes, particularly MC3R and MC4R, which are expressed in central nervous system pathways. Scientific literature describes PT141 as a non-selective melanocortin receptor agonist with distinct central signalling characteristics in laboratory models.

Preclinical studies have evaluated receptor binding affinity, intracellular cyclic AMP activation, and downstream transcriptional responses in cell-based assays. Experimental models have also examined central nervous system signalling pathways influenced by melanocortin receptor activation.

PT141 10mg Canada is supplied strictly for research purposes. All references to receptor biology reflect investigational findings derived from laboratory and clinical research contexts and do not imply authorized therapeutic application of the research-grade material.

Mechanism Overview

PT141 is a cyclic heptapeptide analogue designed to activate melanocortin receptors. In laboratory systems, melanocortin receptor activation stimulates adenylate cyclase activity, increasing intracellular cyclic AMP and initiating downstream signalling cascades.

Unlike α-MSH, PT141 incorporates structural modifications that enhance receptor stability and resistance to enzymatic degradation in experimental environments. Researchers studying PT141 10mg Canada typically evaluate receptor subtype selectivity, signal amplification patterns, and gene expression changes in vitro.

Activation of melanocortin receptors in experimental models has been linked to central nervous system signalling pathways. Mechanistic descriptions remain confined to preclinical and investigational data and are presented for educational purposes only.

Clinical Development Context

PT141 has undergone clinical research in regulated settings exploring melanocortin receptor biology. Certain pharmaceutical formulations have been authorized internationally for defined medical indications under prescription supervision.

However, PT141 10mg, supplied in research-grade format, is categorized strictly as an investigational laboratory compound. It is distinct from authorized prescription preparations and is not approved by Health Canada as a consumer or therapeutic product when provided as a research material.

Academic and clinical research continues to investigate melanocortin receptor modulation and its role in central signalling processes.

Regulatory Status in Canada

Pharmaceutical-grade formulations of PT141 may be regulated under Canadian federal drug legislation when authorized for prescription use.

PT141 10mg, supplied in Canada as a research peptide, is classified separately as an investigational laboratory compound. It is not authorized by Health Canada for therapeutic or consumer use when supplied in research format.

Handling, storage, and study of PT141 10mg in Canada must comply with applicable federal and provincial Canadian regulations governing chemical and biological research materials. Laboratories and research institutions are responsible for maintaining regulatory compliance.

Molecular and Structural Notes

PT141 is a cyclic peptide derived from α-MSH with specific amino acid substitutions that influence receptor binding characteristics in experimental systems. Cyclization of the peptide backbone enhances stability and resistance to proteolytic degradation in vitro.

With a molecular weight of approximately 1025.2 g/mol, PT141 is structurally similar to other melanocortin analogues but differs in its receptor interaction profile due to its amino acid configuration.

PT141 10mg Canada is typically characterized using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry to confirm identity and purity before distribution.

The lyophilized format supports peptide stability during storage when maintained under appropriate laboratory conditions.

Frequently Asked Questions

What is PT141 10mg Canada studied for in research?
PT141 10mg Canada is studied in laboratory settings to investigate melanocortin receptor signalling and central nervous system pathways.

Is PT141 approved for medical use in Canada? Health Canada does notauthorize research-grade PT141 for therapeutic or consumer use. Approved pharmaceutical formulations are regulated separately.

What type of peptide is PT141?
It is a cyclic synthetic melanocortin receptor agonist used in receptor pharmacology research.

Does PT141 10mg Canada contain additives?
Unless specified in the batch documentation, the vial contains only the lyophilized peptide compound.

Can PT141 10mg Canada be used outside research facilities?
No. It is supplied strictly for controlled laboratory and analytical research purposes.

Educational Disclaimer

PT141 10mg Canada is an investigational research peptide supplied solely for laboratory and analytical use. It is not approved by Health Canada as a medication, therapeutic agent, or consumer product when provided in research-grade form.

Information provided on this page is educational in nature and based on publicly available scientific literature describing investigational research contexts. No medical, diagnostic, or therapeutic claims are made.

Study and handling of PT141 10mg Canada should occur only within properly equipped research facilities and in accordance with applicable Canadian regulations and institutional guidelines.